Novo Nordisk announces innovation plans in rare blood disorders’ treatment

Additionally, data from the paradigm study in previously untreated children with haemophilia B under six years of age, treated with once-weekly Refixia prophylaxis for up to six years, will be shared at the congress.

Disclaimer: Short summery, auto-generated by bot, is from article's description and not meant to replace reading the original article.
We do not promote or affiliated with external links in any way.
We have no control over the nature, content and availability of those sites.
All content on this site is meant to be used for information purposes only,
should not be taken as investment advice.
Trademarks and related content are owned by their respective companies.
Read the Terms of Services
Thing Hunt